NVO
Novo Nordisk A/SANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Novo has multiple obesity launch levers now: strong Q1 GLP-1 volume, Wegovy HD in the U.S., and CHMP-backed Wegovy pill and 7.2 mg rollout plans in Europe [#IR-2026-05-06-Q1] [#IR-2026-05-22-WEGOVY-PILL] [#IR-2026-05-22-WEGOVY-7.2MG].
Posture
Constructive
Lead driver
Momentum
What changed
News driver: Novo Raises Forecast as Wegovy Pill Fuels Sales.
What can break
EU launches for Wegovy pill and 7.2 mg still need execution and reimbursement success despite positive CHMP opinions.
Momentum
72
Value
63
Sentiment
71
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $51.00 · Bull $60.00 · Bear $35.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $50.97
Why
Momentum72 · Δ7d +3.6
Value63 · Δ7d +0.2
Sentiment71 · Δ7d +10.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
72
34% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+12.6
Value
63
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.8
Sentiment
71
33% active weight
Current posture
7d trendImproving
Δ7d
+10.9
Δ21d
+16.9
Why this grade
Composite grade A. Momentum 72.5 / Value 62.7 / Sentiment 71.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$197.08B
Beta
1.44
Shares Out
4.44B
P/E (TTM)
14.9
P/S (TTM)
3.72
P/FCF (TTM)
127.96
Rev YoY
+5.1%
EPS YoY
-26.5%
Gross Margin
+82.0%
Op Margin
+42.0%
Net Debt
$11.22B
Current Ratio
0.78
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology